Vireo Growth (VREOF) Notes Payables (2025)
Vireo Growth (VREOF) posted Notes Payables of $200000.0 for Q4 2025, up 24.4% sequentially from $160778.0 in Q3 2025.
Vireo Growth (VREOF) Notes Payables (2025) Analysis & Trends
Vireo Growth has reported Notes Payables for 1 years, with the latest figure at $200000.0 in Q4 2025.
- Quarterly Notes Payables changed N/A year-over-year to $200000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $200000.0 (changed N/A YoY) and the FY2025 annual result came in at $200000.0, changed N/A from the prior year.
- Notes Payables rose to $200000.0 in Q4 2025 per VREOF's latest filing, from $160778.0 in the prior quarter.
- Over five years, Notes Payables peaked at $200000.0 in Q4 2025 and troughed at $160778.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - |
| 10 | Vireo Growth | 482.88 Mn | 340.58 Mn | 95.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 200,000.00 |
| Sep 30, 2025 | 160,778.00 |